Method or Molecule: Judge Dyk Dissents from En Banc Denial in Teva v. Lilly

Дата публикации: 01-10-2026 02:47:05

Federal Circuit denies en banc review in Teva v. Lilly over Judge Dyk's dissent, leaving method claims to an antibody genus intact after Amgen.
Continue reading this post on Patently-O.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Recent Changes in Discretionary Denials of Drug Patent Challenges	0	8.63	09-09-2026
2	Clear but Impossible: Satius v. Samsung Moves Inoperable Claims from Indefiniteness to Enablement	0	9.88	01-10-2026
3	Parting Shot: Mandamus Sends USC v. Google from Judge Albright’s Austin Docket to N.D. Cal.	0	7.13	07-10-2026
4	Tie Goes to the Applicant: The USPTO’s SMED Flowchart	0	8.87	29-09-2026
5	Medivis Gets Some AR Device Patent Claims Cut In Remand	0	5.63	02-10-2026
6	PTAB Invalidates Challenged Claims In Breast Pump Patent	0	6.32	25-09-2026
7	TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation	0	8.67	27-04-2026
8	Novartis Beats Patent Listing Suit Over Entresto	0	7.9	24-09-2026
9	Pre-Suit Validity Investigation: When Must a Patentee Look Before Suing?	0	13.47	05-10-2026
10	Full Fed. Circ. Won't Review NPE Marking, Ramey Sanctions	0	7.69	02-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.62. Источник: patentlyo.com.